HCL Technologies
HCL appoints leadership team in South Korea, Vietnam and Taiwan to
accelerate growth in Asia
HCL Technologies, (HCL), a leading global technology company, has appointed country sales heads to drive and accelerate its presence in Asia. Joonho Moon, Terry Tai and Nguyen Ha Tuan will lead and drive growth in South Korea, Taiwan and Vietnam respectively.
Prior to HCL, Joonho spent more than two decades at Samsung SDS in various leadership positions in sales, business development, corporate marketing, and product strategy.
“I am delighted to be a part of such a dynamic team in HCL Technologies,” said Moon, Country Sales Head, South Korea, HCL Technologies. “I look forward to building upon the company’s current footprint in South Korea and adding to the momentum of growth and expansion in the region.”
Tai is an experienced co-founder, chief strategy officer of a start-up company and the head of sales and business development for about two decades in Taiwan’s IT services industry. He brings a rich experience in cloud technology, artificial intelligence solutions, data storage technology and go-to-market strategy.
“HCL has charted an excellent growth path for itself for the Taiwan market and it is exciting to be a part of that success story from the inception,” said Tai, Country Sales Head, Taiwan, HCL Technologies. “I look forward to helping accelerate our clients’ digital transformation journey and strengthening our presence in the region.”
Tuan has 20 years of experience in the IT Industry. A thought leader and digital transformation practitioner in insurance, retail, banking and finance, public sector, and small- and medium-sized businesses, he has managed digital transformation, security, cloud computing and enterprise applications. Tuan comes to HCL from IBM.
“HCL is a great brand to be associated with, and I am glad to join the team,” said Tuan, Country Sales Head, Vietnam, HCL Technologies. ”I am certain that with its unmatchable services and product offerings, HCL will truly create a niche for itself in the country.”
“HCL has actively expanded its global footprint with its next-generation services and products. South Korea is the highest rated country for innovation and leads in new digital technologies such as 5G and IOT. Taiwan is the nerve center of the global semiconductor industry, which is expected to exponentially grow in the coming decade. Vietnam is one of the fastest growing digital economies and is transforming its society to leapfrog into a knowledge economy,” said C Vijayakumar, CEO, HCL Technologies. “HCL will lean in with its industry leading Engineering and R&D services into these markets. These regions will be led by Sanjay Gupta who is a corporate officer at HCL Technologies.”
“South Korea, Taiwan and Vietnam are growth markets for HCL as we see immense potential for our products and services in these countries,” said Sanjay Gupta, Corporate Vice President, HCL Technologies. “We believe HCL’s deep domain expertise and next-gen technologies will rightly cater to the needs of enterprises and make it the partner of choice in these countries.”
Cadila
Zydus and Bayer announce continuity of their successful Joint Venture
• The joint venture between the two organisations will be extended for 3 years
• Bayer Zydus Pharma will continue to operate in therapies including cardiology, diabetes, women’s health,
ophthalmology and oncology, with new products in the pipeline
• At a time when healthcare is most needed, this JV will continue to focus on innovation-led, patient-centric
offerings and digital health solutions
Bayer (South East Asia) Pte Ltd and Cadila Healthcare Limited today announced the extension of their Joint Venture by three years from June 2021. The companies first entered into an agreement on January 28, 2011 to set up the Joint Venture - Bayer Zydus Pharma Private Limited for the sales and marketing of pharmaceutical products in India, with headquarters in Mumbai.
Over the last ten years, Bayer Zydus Pharma has been a successful partnership combining Bayer’s scientific expertise and commercialization of novel products backed by Cadila Healthcare’s strong India presence. The Joint venture company focused on addressing the unmet healthcare needs of patients in India by providing best-in-class innovative health solutions. During the term of the joint venture, the company also launched some of Bayer’s global innovative assets like Xarelto®, EyleaTM and Visanne® in India. Bayer Zydus Pharma will continue to operate in core therapies including cardiovascular diseases, diabetes, women’s health ,ophthalmology and oncology, with new products in the pipeline. Key products in the company’s pharmaceutical portfolio include Xarelto®, Glucobay®, EyleaTM, Yaz®, Mirena® and Visanne® amongst others. Through strategic and time-honoured alliances with local partners, Bayer Zydus Pharma will continue to offer new-generation therapies to address the nation’s prevailing and emerging health concerns.
Mr. Manoj Saxena, Managing Director, Bayer Zydus Pharma, said, “The Joint Venture with our trusted partner Zydus Cadila has been successful over the last decade in driving scalable reach of our health solutions to patients across the country. We endeavour to carry this momentum forward, harnessing the benefits of our partnership towards delivering innovation-led, patient-centric offerings and digital health tools in India. By sustaining the gains we have made over the years, we aim to fulfill unmet patient needs, strengthen the Indian healthcare ecosystem and translate our vision of ‘Health for All, Hunger for None’ into reality.”
Speaking on the development, Managing Director of Cadila Healthcare Ltd., Dr. Sharvil Patel said, “We have always believed in the power of collaboration and working with partners to create win-win alliances which unlock value for patients and the healthcare system at large. The spirit of partnership in this joint venture has all been about channeling the core strengths of both Zydus and Bayer for the benefit of the patients. By maximizing the reach, enabling access to innovative products for the patients and leveraging expertise for better health outcomes, the JV has set a benchmark. Moving ahead, we see the efforts intensifying as we address a common goal of contributing to a robust and sustainable healthcare system in India.”